Bioxyne Share Price and Company Fundamentals



Price
$0.021
Change
-0.002 (-8.696%)
52 week
0.01 - 0.027

Last traded: Today at 2:57 AM

Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates in two segments, Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and fortified milk formula for nutrition and immune support; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.

Key Metrics

PE ratio

-

PB ratio

7.00

Dividend yield

Beta

1.04

Market cap

$13.44M

Enterprise value

$11.75M

Company profile

Primary activitiesBiotechnology.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.bioxyne.com
Mailing address50 Clarence Street Suite 506 Level 5 Sydney NSW 2000 Australia
Phone / Fax61 2 9078 8180 /
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Bioxyne does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Bioxyne.

NameTitleAgeTotal Pay
Mr. Nam Hoat Chua B.A., BAMD, CEO & Director144.41k
Mr. Guy Adrian Robertson B.Com., C.A., B.Comm(Hons.), CA, MAICDCFO & Company Sec.80k

Profitability and management effectiveness

Profit margin

-28.58%

Operating margin

-16.11%

Return on assets

-6.81%

Return on equity

-24.28%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Bioxyne is 13.44M and its enterprise value is 11.75M. The enterprise value to revenue ratio of BXN is 5.39.

The BXN's stocks Beta value is 1.04 making it 4% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Bioxyne (BXN)

Bioxyne (ASX:BXN) Frequently Asked Questions

1. What is Bioxyne's Stock Symbol?

Bioxyne trades on ASX under the ticker symbol "BXN".

2. What is Bioxyne's stock price today?

One share of BXN stock can currently be purchased for approximately $0.021.

3. How can I contact Bioxyne?

Bioxyne's mailing address is 50 Clarence Street Suite 506 Level 5 Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 9078 8180.

4. What is Bioxyne's official website?

The official website of Bioxyne is http://www.bioxyne.com.

5. Which share registry manages Bioxyne's stock?

Bioxyne's stock is managed by AUTOMIC REGISTRY SERVICES.